 Connection
Eric Wu to Disease-Free Survival
This is a "connection" page, showing publications Eric Wu has written about Disease-Free Survival.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.311 |
|
|
|
-
Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites. Clin Ther. 2016 04; 38(4):905-17.
Score: 0.115
-
Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. Expert Opin Pharmacother. 2015; 16(14):2101-11.
Score: 0.111
-
Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-na?ve patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017 Feb; 20(2):121-128.
Score: 0.030
-
Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer. J Comp Eff Res. 2015 Aug; 4(4):315-26.
Score: 0.028
-
Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 Jun; 31(6):1095-103.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|